IntegraGen Achieves ISO 13485:2016 Certification for the Design, Manufacturing and Distribution of In Vitro Diagnostic Kits

IntegraGen announced that it has earned ISO 13485:2016 certification from Bureau Veritas. This certification indicates that the company’s quality management systems meet the specific standards required for the design, development, production and marketing of in vitro diagnostic kits, and lays the foundation for a continuous improvement process for in (…)  » 

IntegraGen and Twist Bioscience Expand Partnership with Distribution Agreement for SIRIUS and MERCURY Genomic Data Analysis Tools

IntegraGen announces a global distribution agreement with Twist Bioscience for IntegraGen’s portfolio of genomic data analysis tools. The agreement includes distribution rights for SIRIUS™, an online Big Data solution that assists researchers to quickly and intuitively analyze exome data for Mendelian and oncology applications, and MERCURY™, an online (…)  » 

IntegraGen Partners with Twist Bioscience

IntegraGen today announced the addition of Twist Bioscience Corporation’s Human Core Exome Complete Kit, a streamlined library prep and exome enrichment solution, to its next-generation targeted sequencing product offerings. Under the terms of the agreement Twist Bioscience will provide IntegraGen its Human Core Exome Complete Kit for all target (…)  » 

IntegraGen and GoPath Laboratories sign licensing agreement for miR-31-3p test in North America

IntegraGen and GoPath Laboratories announced today the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath’s specialized molecular diagnostic testing portfolio for cancer and enable clinicians to (…)  » 

IntegraGen announces miR-31-3p publication in Oncotarget

IntegraGen announces that results from an analysis of miR-31-3p expression in tumor samples from patients enrolled in the NEW EPOC clinical trial have been published online in Oncotarget. The paper entitled “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a (…)  »